ES2062345T3 - Cromanos sustituidos en el tratamiento del asma, la artritis y enfermedades relacionadas. - Google Patents

Cromanos sustituidos en el tratamiento del asma, la artritis y enfermedades relacionadas.

Info

Publication number
ES2062345T3
ES2062345T3 ES90303443T ES90303443T ES2062345T3 ES 2062345 T3 ES2062345 T3 ES 2062345T3 ES 90303443 T ES90303443 T ES 90303443T ES 90303443 T ES90303443 T ES 90303443T ES 2062345 T3 ES2062345 T3 ES 2062345T3
Authority
ES
Spain
Prior art keywords
treatment
asthma
arthritis
related diseases
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90303443T
Other languages
English (en)
Inventor
James Frederick Eggler
Hiroko Masamune
Anthony Marfat
Lawrence Sherman Melvin Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2062345T3 publication Critical patent/ES2062345T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COLORANTES SUSTITUIDOS LOS CUALES SE EMPLEAN EN LA PREVENCION O TRATAMIENTO DE ASMA, ARTRITIS, PSORIASIS, ULCERAS, INFARTO DE MIOCARDIO, ATAQUES Y ESTADOS DE ENFERMEDADES RELACIONADAS EN MAMIFEROS, MEDIANTE LA INHIBICION DEL ENZIMA 5-LIPOOXIGENASA. COMPOSICIONES FARMACEUTICAS DE ELLOS Y UN METODO DE TRATAMIENTO CON ELLAS, Y PRODUCTOS INTERMEDIOS USADOS EN SU SINTESIS.
ES90303443T 1989-04-07 1990-03-30 Cromanos sustituidos en el tratamiento del asma, la artritis y enfermedades relacionadas. Expired - Lifetime ES2062345T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/001457 WO1990012010A1 (en) 1989-04-07 1989-04-07 Substituted chromans in the treatment of asthma, arthritis and related diseases

Publications (1)

Publication Number Publication Date
ES2062345T3 true ES2062345T3 (es) 1994-12-16

Family

ID=22214926

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90303443T Expired - Lifetime ES2062345T3 (es) 1989-04-07 1990-03-30 Cromanos sustituidos en el tratamiento del asma, la artritis y enfermedades relacionadas.

Country Status (12)

Country Link
US (1) US5298512A (es)
EP (1) EP0391625B1 (es)
JP (1) JPH0753726B2 (es)
AT (1) ATE100804T1 (es)
CA (1) CA2013894A1 (es)
DE (1) DE69006243T2 (es)
DK (1) DK0391625T3 (es)
ES (1) ES2062345T3 (es)
FI (1) FI914683A7 (es)
IE (1) IE901241L (es)
PT (1) PT93674A (es)
WO (1) WO1990012010A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5149703A (en) * 1991-09-06 1992-09-22 Merck Frosst Canada, Inc. Quinoline-substituted chromans and related compounds as leukotriene antagonists
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
US5451603A (en) * 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5698550A (en) * 1993-06-14 1997-12-16 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
US5482942A (en) * 1994-06-28 1996-01-09 American Home Products Corporation (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
CA2375275A1 (en) 1999-06-22 2000-12-28 Mount Sinai Hospital Difuropyrone derivatives
EP1579010A4 (en) * 2002-10-17 2010-07-21 Decode Genetics Ehf SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US10772652B2 (en) 2015-01-28 2020-09-15 Covidien Lp Tissue resection system
US10799264B2 (en) 2015-06-18 2020-10-13 Covidien Lp Surgical instrument with suction control
CA3035999C (en) * 2017-09-07 2021-01-05 Syaulan S. YANG Benzene fused heterocyclic derivatives and pharmaceutical composition comprising the same
US11883058B2 (en) 2019-03-26 2024-01-30 Covidien Lp Jaw members, end effector assemblies, and ultrasonic surgical instruments including the same
EP4126835B1 (en) * 2020-03-31 2026-02-18 Janssen Pharmaceutica NV Inhibitors of antigen presentation by hla-dr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553093A (en) * 1965-03-19 1971-01-05 Xerox Corp Color photoelectrophoretic imaging process
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
US4127669A (en) * 1977-10-13 1978-11-28 Warner-Lambert Company [(4-Oxo-4H-1-benzopyran-3-yl)oxy] acetic acids and derivatives
US4563468A (en) * 1979-09-13 1986-01-07 Burroughs Wellcome Co. Chemotherapeutic agents
EP0126311B1 (en) * 1983-05-18 1989-09-13 Beecham Group Plc Benzopyran derivatives.
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US4889941A (en) * 1987-04-23 1989-12-26 Fisons Corporation Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos

Also Published As

Publication number Publication date
FI914683A0 (fi) 1991-10-04
US5298512A (en) 1994-03-29
JPH0753726B2 (ja) 1995-06-07
DK0391625T3 (da) 1994-02-28
EP0391625B1 (en) 1994-01-26
EP0391625A1 (en) 1990-10-10
WO1990012010A1 (en) 1990-10-18
PT93674A (pt) 1990-11-20
IE901241L (en) 1990-10-07
ATE100804T1 (de) 1994-02-15
JPH02290869A (ja) 1990-11-30
DE69006243T2 (de) 1994-05-05
CA2013894A1 (en) 1990-10-07
FI914683A7 (fi) 1991-10-04
DE69006243D1 (de) 1994-03-10

Similar Documents

Publication Publication Date Title
ES2058306T3 (es) Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas.
DK0391625T3 (da) Substituerede chromaner til behandling af astma, arthritis og beslægtede sygdomme
DE69312218D1 (de) Redistribution von organischen Polycarbonatzusammensetzungen
ES536499A0 (es) Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.
IT8067166A0 (it) Composizione induribile con luce ultravioletta per la produzione di rivestimenti di bassa lucentezza
FI904181A0 (fi) Tislauslaitteisto vetyperoksidin valmistamiseksi
ES2061681T3 (es) Cromados sustituidos y compuestos relacionados en el tratamiento del asma.
ES2109229T3 (es) Sulfonamidas sustituidas y compuestos relacionados para el tratamiento del asma, la artritis y enfermedades relacionadas.
PT1121364E (pt) Procedimento para a sintese de epotilona b e seus derivados, bem como de produtos intermediarios para este procedimento
ES2061247T3 (es) Imidazo (4,5-c) piridinas con actividad antagonista del paf.
ES2063974T3 (es) Una nueva forma estable de cefradina, un proceso para su produccion y compuestos intermedios usados en tal proceso.
IT1197713B (it) Dicloro-derivati della serie del 16 alfa-metil pregnano,procedimento per la produzione,loro applicazione come medicamenti e composizioni che li contengono
PT666755E (pt) Inibicao da infeccao pelo vih
ES2062332T3 (es) Benzoxazolonas antiinflamatorias.
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.
DE59406501D1 (de) Substituierte iminoacetonitrile mit myokardprotektiver wirkung
DE59405189D1 (de) Neues diphenylhexen
ES1025952U (es) Elementos para mueble modular.
IT8423664A0 (it) Realizzate in applicazione al detto metodo per la produzione metodo. industriale di calzature, in particolare ciabatte, di notevole leggerezza ed utilizzabili sia da casa che all'aperto, e calzature
IT7922928V0 (it) Impianto per la produzione di metano da liquami in genere e simili.
IT8619899A0 (it) Immino-imidazolidine sostituite, dotate di particolari proprieta'terapeutiche, loro processo di sintensi e composizioni farmaceutiche.
ITVI930098A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 391625

Country of ref document: ES